Explore the words cloud of the CARDIATEAM project. It provides you a very rough idea of what is the project "CARDIATEAM" about.
The following table provides information about the project.
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
|Coordinator Country||France [FR]|
|Total cost||12˙882˙500 €|
|EC max contribution||6˙700˙000 € (52%)|
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
|Duration (year-month-day)||from 2019-03-01 to 2024-02-29|
Take a look of project's partnership.
|1||INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE||FR (PARIS)||coordinator||1˙240˙727.00|
|2||CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P.||ES (MADRID)||participant||655˙500.00|
|3||SIB INSTITUT SUISSE DE BIOINFORMATIQUE||CH (GENEVE)||participant||648˙000.00|
|4||STICHTING NETHERLANDS HEART INSTITUTE||NL (UTRECHT)||participant||605˙000.00|
|5||LUXEMBOURG INSTITUTE OF HEALTH||LU (LUXEMBOURG)||participant||588˙156.00|
|6||UNIVERSITY OF DUNDEE||UK (DUNDEE)||participant||550˙001.00|
|7||UNIVERSITA DEGLI STUDI DI TORINO||IT (TORINO)||participant||407˙616.00|
|9||INSERM TRANSFERT SA||FR (PARIS)||participant||310˙250.00|
|10||HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH||DE (NEUHERBERG)||participant||269˙526.00|
|11||UNIVERSITE D'AIX MARSEILLE||FR (Marseille)||participant||213˙375.00|
|12||HOSPICES CIVILS DE LYON||FR (LYON)||participant||202˙708.00|
|13||ASSISTANCE PUBLIQUE HOPITAUX DE PARIS||FR (PARIS)||participant||200˙000.00|
|14||UNIVERSITAETSKLINIKUM AACHEN||DE (AACHEN)||participant||138˙750.00|
|15||UNIVERSITATSKLINIKUM HEIDELBERG||DE (HEIDELBERG)||participant||124˙975.00|
|16||KATHOLIEKE UNIVERSITEIT LEUVEN||BE (LEUVEN)||participant||94˙782.00|
|17||THE QUEEN'S UNIVERSITY OF BELFAST||UK (BELFAST)||participant||30˙000.00|
|18||METABRAIN RESEARCH||FR (MAISONS-ALFORT)||participant||28˙150.00|
|19||BAYER AKTIENGESELLSCHAFT||DE (Leverkusen)||participant||0.00|
|20||Eli Lilly and Company Limited||UK (Basingstoke)||participant||0.00|
|21||SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT||FR (Chilly Mazarin)||participant||0.00|
A rapidly evolving epidemic in Type 2 Diabetes (T2DM) is afflicting all ages, sexes and socioeconomic classes which includes serious comorbidities such as heart diseases. While ischaemic heart disease represents the major cause of death of T2DM patients, heart failure (80% of Heart Failure with preserved Ejection Fraction) is the second most common cardiovascular disease in T2DM patients. The aim of CARDIATEAM is to determine whether T2DM represents a central mechanism contributing to the pathogenesis and progression of a specific cardiomyopathy, called “diabetic cardiomyopathy” (DCM), assessing whether DCM is unique and distinct from the other forms of heart failure. To achieve this aim CARDIATEAM will build up a deeply phenotyped cohort, including an innovative imaging protocol, based on privileged access within the CARDIATEAM to already existing highly pertinent cohorts of diabetes and heart failure patients and control groups. Central biobanking of the cohort samples will allow detailed omics analysis that will feed together with the phenotype and imaging data into the central CARDIATEAM database. The data gathered will enable unsupervised machine-learning for clustering this heterogeneous population on phenotypic differences beyond diabetes. State-of-the-art big-data processing techniques and disease modeling will allow for controlling for common confounders such as BMI, smoking, age and blood pressure and will finally lead to the identification of new imaging and molecular biomarkers as well as understanding the taxonomy of the development and progression of DCM. Tailored preclinical models will be developed to explore the identified pathways revealing new therapeutic targets. The results of CARDIATEAM will be able to impact clinical care with the stratification of patients into risk groups of developing DCM, earlier diagnosis of DCM and an improvement of therapy thanks to better assessment of underlying pathophysiology and identification of new biomarkers.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CARDIATEAM" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "CARDIATEAM" are provided by the European Opendata Portal: CORDIS opendata.
Bringing a prophylactic Ebola vaccine to licensureRead More
Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitorsRead More
Parkinson Disease with Mild cognition Impairment treated with Nicotinic agonist DrugRead More